- Conditions
- Ocular Hypertension, Open-angle Glaucoma
- Interventions
- AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID
- Drug · Other
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- Up to 99 Years
- Enrollment
- 756 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 57
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- AR-12286 0.5% Ophthalmic Solution
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Chronic Angle-closure Glaucoma
- Interventions
- Rho-Kinase Inhibitor
- Drug
- Lead sponsor
- New York Glaucoma Research Institute
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo
- Drug · Other
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 708 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
- Conditions
- Elevated Intraocular Pressure
- Interventions
- AR-12286, AR-12286 vehicle
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 8
- States / cities
- Pasadena, California • Petaluma, California • Brooksville, Florida + 5 more
- Conditions
- Heart Failure
- Interventions
- LCZ 696, Icatibant, placebo, Para-aminohippurate, Iohexol
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Anesthesia
- Interventions
- Blood drawn
- Diagnostic Test
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Autonomic Nervous System Diseases, Orthostatic Hypotension, Dopamine Beta-Hydroxylase Deficiency, Orthostatic Intolerance
- Interventions
- Droxidopa Oral Product
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Supine Hypotensive Syndrome, Cesarean Section Complications, Anesthesia Complication
- Interventions
- Blood Pressure Cuff
- Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension
- Interventions
- SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%, SBI-100 Ophthalmic Emulsion, Placebo
- Drug
- Lead sponsor
- Skye Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Glendale, California • Newport Beach, California • Cranberry Township, Pennsylvania
- Conditions
- Young Adults, Hypertension, Post-Exercise Hypotension, Circadian Rhythm
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- Freda Patterson
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Hypertension, Prehypertension
- Interventions
- High fat dairy, Plant-based
- Dietary Supplement
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 15
- States / cities
- New Haven, Connecticut • Roswell, Georgia • Shawnee Mission, Kansas + 11 more
- Conditions
- Blunt Trauma, Penetrating Wound, Hemorrhagic Shock
- Interventions
- 0.9% Sodium Chloride 250 mL bolus, 0.9% Sodium Chloride 2000 mL bolus
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- VS101 Insert Dose A, VS101 Insert Dose B, VS101 Insert Dose C, Latanoprost 0.005% eye drops
- Drug
- Lead sponsor
- ViSci Ltd.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Bellevue, Washington
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Septicemia
- Interventions
- Electronic Health Record Review
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prehypertension, Stage-1 Hypertension
- Interventions
- Non-fat dairy, Add 4 servings fruit
- Dietary Supplement
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Hypotensive
- Interventions
- Landmark Procedure, Ultrasound Guided Procedure
- Procedure
- Lead sponsor
- Antonios Likourezos
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Hypotension, Pregnancy
- Interventions
- ondansetron, placebo
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Ocular Hypertension, Open-angle Glaucoma
- Interventions
- Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo
- Drug · Other
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
- Conditions
- Leukemia, Lymphoma, Paraproteinemias, Multiple Myeloma, Myelodysplastic Syndromes
- Interventions
- USCOM scan, Fluid Bolus
- Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Glaucoma
- Interventions
- AR-12286 0.5% ophthalmic solution, AR-12286 0.25% Ophthalmic solution, Latanoprost ophthalmic solution
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 18
- States / cities
- Inglewood, California • Petaluma, California • Poway, California + 15 more